ADRENERGIC β2 AGONISTS IN THERAPY OF PATIENTS 2 WITH BRONCHIAL ASTHMA

D. Popović ,
D. Popović

Public health care „Dr Mladen Stojanoviæ“ , Bačka Palanka , Serbia

M. Đurić ,
M. Đurić

Institut for lung diseases, Sremska Kamenica, Medical faculty , Novi Sad , Serbia

N. Naumović ,
N. Naumović

Department for physiology, Medical faculty , Novi Sad , Serbia

V. Ivetić ,
V. Ivetić

Department for physiology, Medical faculty , Novi Sad , Serbia

N. Sečen ,
N. Sečen

Institut for lung diseases, Sremska Kamenica, Medical faculty , Novi Sad , Serbia

Z. Lazić ,
Z. Lazić

Institut for lung diseases, Medical faculty , Kragujevac , Serbia

Z. Lazić
Z. Lazić

Institut for lung diseases, Medical faculty , Kragujevac , Serbia

Published: 01.12.2009.

Volume 37, Issue 2 (2009)

pp. 143-147;

https://doi.org/10.70949/pramed200902312P

Abstract

Bronchial asthma is the syndrome, characterized with chronic inflammation, hyperreactivity and obstruction of the respiratory pathways, accompanied with consequential symptoms and remodeling of the respiratory pathways. Application of inhaled corticosteroids accompanied with appropriate education of patients, significantly improve therapeutic treatment and outcome of the asthma. But, improvement of the lung function and patients subjective state is remarkable better yif inhaled corticosteroids are combined with adrenergic â2 agonists, than if the dose of inhaled corticosteroids is increased. So, according to Global initiative for asthma and clinical results long acting adrenergic â2 agonists in combination with inhaled corticosteroids are most efficient in asthma treatment and establishment and conservation of bronchial asthma control. 

Keywords

References

1.
Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention.
2.
Melland B. The treatment of spasmodic asthma by the hypodermic injection of adrenalin. Lancet. 1407–11.
3.
Pavlov N. Funkcionalna dijagnostika i nadzor djece s astmom. Paediatr Croat. 51(1):85–90.
4.
Umland SP, Schleimer RP, Johnston SL. Review of the molecular and cellular mechanisms of action of glucocorticoids for use in asthma. Pulm Pharmacol Ther. 15(1):35–50.
5.
Graeme P, Currie SS. What about add-on second-line controller therapy? Chest. 127:1077–8.

Citation

Copyright

Article metrics

Google scholar: See link

The statements, opinions and data contained in the journal are solely those of the individual authors and contributors and not of the publisher and the editor(s). We stay neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Most read articles

Indexed by